A new theranostic drug targets different cancer types.

Published Date: 28 Jun 2023

In preclinical models, a recently identified radionuclide-based agent (CB-2PA-NT) has been demonstrated to have high tumor uptake, sustained tumor retention, and high contrast, making it an excellent candidate for a novel theranostics strategy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

2.

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

3.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

4.

Use of social media during pregnancy may increase depression.

5.

Are ultramarathon runners really at increased risk of bowel cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot